Boltz
AI Drug Discovery · Biotech AI
Boltz raises $110M Series A to scale AI drug discovery models
November 18, 2026
Raised
$110M
Usage of its molecular design software has grown fifty-fold since June as top pharma firms sign on.
- Boltz raised $110 million in a Series A led by Bessemer Venture Partners, less than a year after its $28 million seed round.
- The London-based lab, spun out of MIT's CSAIL and Jameel Clinic, builds AI foundation models that predict and design how proteins and small molecules bind, speeding early-stage drug discovery.
- Six of the world's 20 largest pharmaceutical companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb, now use its Boltz Lab platform.
- Molecular token usage among paying customers has grown 50-fold since June, when Boltz released its first proprietary models, BoltzMol-1 and BoltzProt-1.
- Boltz's earlier open-source models, which match AlphaFold3's performance, have been downloaded more than 5 million times and are used by over 100,000 scientists.
- The round signals investors betting that AI-designed molecules, not just AI-run labs, will become the default tool for early-stage drug discovery.
Lead Investors
Bessemer Venture Partners